A Study for Assessing the Safety of Hanita Glaucoma Shunt in Glaucoma Patients

Glaucoma Clinical Trial

Official title:

A Study for Assessing the Safety of Hanita Glaucoma Shunt in Glaucoma Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04796883
• Other study ID #: HGS-01
• Status: Completed
• Phase: N/A
• Start date: June 30, 2015
• Est. completion date: November 15, 2021

Study information

• Verified date: February 2022
• Source: Hanita Lenses
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The HANITA Glaucoma Filtration Device is intended to reduce intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed.

Description:

Study Design:

This study is a prospective, single-arm single-center, open-label study.

Study population:

Men and women diagnosed with open-angle glaucoma who require glaucoma surgery procedures that meet the inclusion/exclusion criteria and provide written informed consent will be enrolled in the study.

Enrollment:

A total of 30 subjects will be enrolled:

15 patients will be implanted according to procedure 1 (see section 8.7), at completion additional 15 patients will be implanted according to procedure 2 (see section 8.7)

Investigational sites:

One (1) center will participate in this study.

Duration of Subject participation:

Completion of active enrolment is anticipated to last approximately 6 months. The primary endpoint will be achieved when the final study subject has completed 6 months follow-up.

Study Group:

A single study group. This is a single-arm design; there is no control device in this study.

Visits & Procedures Pre-operative visit: 0-3 months prior to the implantation procedure. The visit will include the subject's qualification assessment for inclusion/exclusion criteria as described above. Informed consent must be signed.

Complete anamnesis will be taken including the subject's medical complaints, medical history, and medication use. Ophthalmic examinations as well as ultrasound biomicroscopy.

Surgical procedure: Procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt will be implanted.

Follow-up: All subjects will have regular follow-up visits at 1 and 7 days and on 1, 3, and 6 months post-implantation. 1-year post-operative evaluation is optional at the sponsor's discretion. All postoperative visits will include a complete ophthalmic examination,

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 15, 2021
• Est. primary completion date: November 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is between 40 and 80 years of age

• Subject diagnosed with primary Open-angle glaucoma

• Subject is Diagnosed with glaucoma uncontrolled by medical therapy which meets at least one of the following criteria:

• Failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery or tube shunt)

• Failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode therapy)

• Have any other condition (e.g., conjunctival scarring, uveitis) in which a conventional incisional glaucoma surgery like trabeculectomy would be more likely to fail than for a person with uncomplicated primary open-angle glaucoma

• Under present-day criteria subject is a candidate for glaucoma surgery

• Intraocular pressures of the eye above or equal to 25 mmHg with or without medication

• The angle should be grade 3 in at least the 180º superior and not less than grade 2 at any level of the angle

• Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

Exclusion Criteria:

• Subject diagnosed with primary angle-closure glaucoma (PACG)

• Subject diagnosed with normal-tension glaucoma (NTG)

• Subject diagnosed with secondary glaucoma

• Subject diagnosed with neovascular glaucoma

• Patient eyes with no light perception vision

• Patient eyes with the need for a combined glaucoma procedure or anticipated need for additional ocular surgery or retinal laser procedure within the 6-month follow-up period

• Patient eyes that have failed laser trabeculoplasty but have not met the stated inclusion criteria

• The subject has best-corrected visual acuity (BCVA) worse than 20/200 in the non-study eye

• Subject consumes the anti aggregating or anticoagulant and cannot suspend the use at least four days prior to the procedure, and antiplatelet drugs one week before

• The subject is diagnosed with glaucoma-related to other comorbidities (especially neovascular glaucoma, inflammatory glaucomas, glaucomas associated with hemorrhages and pseudoexfoliation)

• Subject with inadequate space in the anterior chamber and/or angle as determined by slit-lamp examination and gonioscopy

• The subject is diagnosed with active anterior segment intraocular inflammation

• The subject is obligated to previous participation in another study with any investigational drug or device within the past 30 days

• Subject is pregnant

Related Conditions & MeSH terms

• Glaucoma

Intervention

Device:
• Hanita Glaucoma shunt Ver.3.2
The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.

Locations

Country	Name	City	State
Spain	VISSUM	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Hanita Lenses

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VISUAL ACUITY	• Distance (far) manifest refraction and the testing distance used will be recorded on the case report forms. Manifest refraction will be determined using the maximum plus for best visual acuity method. The distance manifest refraction will be done with a distance adjusted chart but not less than 4 meters. The actual manifest refraction distance will be noted on the case report forms.; Visual acuity will be measured with ETDRS format charts for distance and near. Results will be recorded in a LogMar scale.	1 year
Primary	SLIT LAMP EXAM	The slit lamp exam will include the measurement of aqueous cell and flare, and the measurement of corneal edema by a standard grading system. It will also include an evaluation for the presence of pupillary irregularities, iris atrophy and pigment dispersion. A gonioscopic exam using a consistent grading system at each site will also be conducted.; For the evaluation of aqueous cells and flare, use a slit lamp beam 0.3 mm wide and 1 mm high, and use the following grading: Cells none (0) = no cells seen trace (+1) = 1-5 cells seen mild (+2) = 6-15 cells seen moderate (+3) = 16-30 cells seen severe (+4) = > 30 cells seen; Flare none (0) = No Tyndall effect trace (+1) = Tyndall effect barely discernible mild (+2) = Tyndall beam in anterior chamber is mildly intense moderate (+3) = Tyndall beam in anterior chamber is moderately intense severe (+4) = Tyndall beam is severely intense. The aqueous has a white and milky appearance.	1 year
Primary	MEASUREMENT OF INTRAOCULAR PRESSURE	Intraocular pressure will be measured using Goldmann applanation tonometry or other validated methods.	1 year